Table 2.
Comparison of hospitalization and mortality rates between Cohort A and Cohort B.
| Cohort B (January 2021-March 2022) | Cohort A (March-July 2020, described in reference 1) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Age(yr, IQR) | Sex (n, % male) | IgRT(n, %) | pAbx (n, %) | IS(n, %) | Hospital-ised(n, %) | Deaths (n) | Inpatient mortality (%) | IFR (%) | n | Age (yr, IQR) | Sex(n, % male) | IgRT (n, %) | pAbx(n, %) | IS(n, %) | Hospital-ised(n, %) | Deaths(n) | Inpatient mortality (%) | IFR (%) | p-value (hospital-isation) | p value (inpatient mortality) | p value (IFR) | ||
| Primary Immunodeficiency (all) | 117 |
45
(33-59) |
62 (52.9) |
98
(83.8) |
60 (51.2) | 19 (16.2) |
21
(17.9) |
4 | 19.0 | 3.42 | 60 | 42.0 (28.0-58.2) | 26 (43.3) |
42 (70.0) | 32 (53.3) | 11 (18.3) |
32 (53.3) |
12 | 37.5 | 20.0 | < 0.0001 | 0.15 | 0.0003 | |
| Primary Immunodeficiency (untreated, no prior COVID-19, 2x vaccinated) | 26 | 45 (35-61) |
13 (50.0) | 23 (88.4) |
15 (57.6) | 7 (26.9) | 0 (0.0) |
0 | 0.0 | 0.0 | <0.0001 | - | 0.01 | |||||||||||
|
Common variable immunodeficiency
(all) |
50 |
45
(37-60) |
24 (48.0) |
48
(96.0) |
29 (58.0) | 11 (22.0) |
10
(20.0) |
1 | 10.0 | 2.0 | 23 | 54.0 (31.8-70.8) | 9 (39.1) |
20 (87.0) | 11 (47.8) | 4 (17.4) |
13 (56.5) |
8 | 61.5 | 34.8 | 0.002 | 0.01 | <0.0001 | |
| CVID (untreated, no prior COVID-19, 2x vaccinated) | 13 | 44 (35-53) |
6 (46.2) | 13 (100.0) |
8 (61.5) | 3 (23.1) | 0 (0.0) |
0 | 0.0 | 0.0 | 0.0007 | - | 0.02 | |||||||||||
| Secondary Immunodeficiency (all) | 38 |
57
(48-65) |
17 (44.7) |
27
(71.1) |
19 (50.0) | 14 (36.8) |
7
(18.4) |
3 | 42.8 | 7.89 | 33 | 64.5 (56.0-79.8) | 15 (45.5) |
20 (87.0) | 25 (75.8) | 12 (36.3) |
25 (75.8) |
11 | 44.0 | 33.3 | < 0.0001 | 0.96 | 0.007 | |
| Secondary Immunodeficiency (untreated, no prior COVID-19, 2x vaccinated) | 13 | 59 (44-63) |
6 (46.1) | 8 (61.5) |
6 (46.1) | 6 (46.1) | 0 (0.0) |
0 | 0.0 | 0.0 | <0.0001 | - | 0.02 | |||||||||||
For continuous variables the median and interquartile range is provided. Categorical variables are compared using the Chi-square test. IgRT – immunoglobulin replacement therapy, pAbx – prophylactic antibiotics, IS – current immune suppression, IFR – infection-fatality ratio, CVID – common variable immunodeficiency, COVID-19 – Coronavirus disease-19. Untreated refers to individuals who received no specific inpatient or outpatient treatment for COVID-19 (i.e. antivirals, monoclonal antibodies, steroids or biologic therapies). In bold to draw attention to them, they are primary headings for the tables.